In this Bayesian NMA of 22 randomized phase II or III trials with a total of 5237 patients, we indirectly compared survival outcomes and AEs of the seven treatment nodes (ICI monotherapy, ICI plus doublet chemotherapy, double ICIs with or without doublet chemotherapy, bevacizumab plus doublet chemotherapy with or without ICI, and doublet chemotherapy) as first-line treatment for advanced NSCLC with high PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.